Metastatic Small Cell Lung Cancer Masquerading as a Pancreatic Mass: A Case Report

TL;DR

A case of lung cancer spreading to the pancreas was initially mistaken for pancreatic cancer, highlighting the need for careful diagnosis and further research.

Contribution

This case report adds to the understanding of rare SCLC metastasis to the pancreas and emphasizes diagnostic challenges.

Findings

A 59-year-old woman presented with symptoms resembling pancreatic cancer but was diagnosed with metastatic SCLC in the pancreas.

The case underscores the importance of considering metastatic SCLC in the differential diagnosis of pancreatic masses.

Further research is needed to understand the mechanisms of SCLC metastasis to the pancreas.

Abstract

Small cell lung cancer (SCLC) is notorious for its aggressive behavior and propensity for metastasis. Although metastasis to the pancreas from SCLC is relatively rare, it warrants attention due to its overlapping symptomatology with primary pancreatic malignancies and other abdominal pathologies (such as those involving the liver or gallbladder). Despite recent advances, the mechanisms driving SCLC metastasis to the pancreas remain elusive, providing challenges in diagnosis and treatment.

This case report details the presentation of a 59-year-old woman with SCLC metastasis to the pancreas, initially masquerading as primary pancreatic carcinoma, as highlighted by her presenting symptoms of jaundice, weight loss, and abdominal pain. Diagnostic workup, including imaging studies and tissue sampling, confirmed the unexpected presence of metastatic SCLC in the pancreas. The patient was ultimately transferred to a tertiary care facility for further workup.

This case serves as a reminder to maintain a broad differential diagnosis, particularly in the face of such an unusual presentation. It also highlights the need for further research to elucidate the molecular and cellular mechanisms driving SCLC metastasis to the pancreas, with the ultimate goal of improving diagnostic accuracy and therapeutic outcomes for patients with this aggressive disease.

Figures